1. Inicio
  2. Publicaciones
  3. Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Alonso Salinas G.L.
  • Martínez León A.
  • Aguiar Cano D.
  • Esteban-Fernández A.
  • Viéitez Flórez J.M.
  • del Prado Díaz S.
  • Górriz-Magaña J.
  • de Lara Delgado G.
  • González-Manzanares R.
  • Caravaca-Pérez P.
  • Pastor-Pérez F.J.
  • Valdivieso-Moré S.
  • Quiles J.
  • Ponz I.
  • Escolar V.
  • Boada Lincango E.O.
  • Báez-Ferrer N.
  • Gallego G.
  • Gutiérrez de la Varga L.
  • Codina P.
  • Recio Mayoral A.
  • Fort A.
  • Pinilla Lozano M.J.
  • González-Calle D.
  • Gómez-Otero I.
  • Salazar Mosteiro C.
  • Cobo M.
  • Piqueras-Flores J.
  • Bonanad C.
  • Huerta A.
  • Ferré Vallverdú M.
  • Díez-Villanueva P.

Grupos

Abstract

Aims: Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce. We aim to assess both the baseline clinical profile and prognostic role of finerenone in patients with HF, irrespective of ejection fraction. Methods and results: The study is a multicentre, observational registry, including regional and tertiary hospitals. The registry incorporates contributions from cardiology, internal medicine, and nephrology departments, ensuring comprehensive data collection. Patients with previous history of decompensated HF and elevated natriuretic peptides (NPs) will be included and classified into two groups: Those initiating finerenone will constitute the study cohort, with a 1:1 matched control cohort including those patients not receiving finerenone. Follow-up will occur at 6 and 12 months (and optional 3 and 5 years). Endpoints will include the incidence of HF exacerbations requiring intravenous therapy, hospitalizations, renal replacement therapy, and mortality due to cardiovascular or renal causes. Conclusions: This study will provide valuable real-world evidence on the clinical effectiveness and safety of finerenone across a wide range of HF patients, including those with reduced, mildly reduced, and preserved ejection fraction. By leveraging a large, representative, and controlled cohort, the findings aim to enhance clinical decision-making and optimize the use of finerenone in routine practice, particularly in high-risk patients with complex co-morbidities. © 2025 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Datos de la publicación

ISSN/ISSNe:
2055-5822, 2055-5822

ESC Heart Failure  OXFORD UNIV PRESS

Tipo:
Article
Páginas:
3163-3172
PubMed:
40017333
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,797 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Naphthyridines; Prognosis; Registries; Stroke Volume; creatinine; finerenone; finerenone; mineralocorticoid antagonist; naphthyridine derivative; adult; Article; cardiovascular mortality; clinical decision making; clinical outcome; clinical practice; clinical utility; cohort analysis; decision making; diastolic blood pressure; drug safety; female; follow up; heart ejection fraction; heart failure; heart left ventricle ejection fraction; hospitalization; human; hyperkalemia; hypertension; male; morbidity; mortality; multicenter study; observational study; outcome assessment; prevalence; prospective study; systolic blood pressure; tertiary care center; clinical trial; drug effect; drug therapy; heart stroke volume; pathophysiology; physiology; prognosis; register

Cita

Compartir